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Business and Professions
Chapter 304: Broadening the Scope of Alternative and




Business and Professions Code § 2234.1 (amended).
AB 592 (Yee); 2005 STAT. Ch. 304.
"I started getting sick in 1988; I became too ill to work in 1991. It was
not until the year 2000 that I was finally diagnosed with [persistent]
Lyme disease.... [Elven then I had to fight to educate my physician in
order to be treated with long-term antibiotics."
-Melissa Kaplan'
I. INTRODUCTION
In 1978, a hiker from Sonoma County experienced the first reported human case
of Lyme disease in California.2 Between 1994 and 2003, over 850 cases of Lyme
disease were reported to the State Department of Health Services from fifty-four of
the fifty-eight California counties.
Despite being the most frequently reported vector-borne disease in California,
doctors estimate patients severely underreport symptoms and doctors themselves
frequently misdiagnose the disease Melissa Kaplan's letter represents more than
fifty individual letters from proponents of Chapter 304, which describe the plight that
Lyme disease patients in California must endure before receiving appropriate
medical care or even a proper diagnosis of their disease.6 The National Academy of
Science's Institute of Medicine ("IOM") has reported that a new best practice can
1. Letter from Melissa Kaplan, to Assembly Member Leland Y. Yee, Cal. State Assembly (Apr. 4, 2005)
(on file with the McGeorge Law Review).
2. An Update on the Epidemiology of Lyme Disease in California, ACTION REPORT (Med. Bd. of Cal.),
Oct. 2001, at 6 [hereinafter Epidemiology Update] (on file with the McGeorege Law Review).
3. See CAL. DEP'T OF HEALTH SERVS., VECTOR-BORNE DISEASES IN CALIFORNIA, 2003 ANNUAL
REPORT 15 (Aug. 2004) (charting the reported Lyme disease cases by county of residence in California from
1993-2003).
4. Epidemiology Update, supra note 2.
5. See Lyme Disease: The Hidden Epidemic: Hearing Before the Senate Heath and Human Servs.
Comm., (Feb. 25, 2004) (testimony of Raphael Stricker, M.D.) [hereinafter Stricker Testimony] (testifying on
the state of Lyme disease in California).
6. See, e.g., Letters from Judith Ain et al., to Assembly Member Leland Y. Yee, Cal. State Assembly, &
Tracy Rhine, Consultant, Assembly Bus. and Prof. Comm. (Multiple dates) (on file with the McGeorge Law
Review) (expressing support for Chapter 304 and describing individual experiences receiving diagnosis and
treatment for the disease).
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take up to seventeen years to reach the average doctor.' Lyme disease patients are a
current, prime example of those who suffer as a result of this lag time. With Chapter
304, the California Legislature hopes to accelerate the process of reaching California
patients with the new best practice for treating persistent Lyme disease s
II. LYME DISEASE BACKGROUND
Infectious ticks transmit Lyme disease to humans by their bite. 9 Lyme disease
was first discovered in Lyme, Connecticut in 1975 '0 and has ever since divided
the medical community." The controversy rests between two very different
schools of medical thought, which advocate two different standards of care for
Lyme disease treatment.1
2
The dominant school believes that Lyme disease is "hard to catch and easy to
cure"'' 3 and that persistent Lyme disease is either very rare or does not exist at
all. 4 The dominant school, therefore, treats Lyme disease with antibiotics for a
term of no greater than thirty days.' 5 The clinical guidelines of the Infectious
Diseases Society of America (IDSA) embrace this traditional school of thought
and standard of care.'
6
In contrast, the emerging school of thought believes that Lyme disease is
underreported,' 7 is "[not] hard to catch and [not] easy to cure,"' 8 and often fails to
respond to the dominant standard of care.' 9 The emerging school of thought
believes that the thirty-day antibiotic regimen (the dominant standard of care) is
7. CAL. Bus. & PROF. CODE § 2234.1(c) (amended by Chapter 304); see The Chasm in Quality: Select
Indicators from Recent Reports, INST. OF MED., http://www.iom.edu/subpage. asp?id=14980, (last visited June
17, 2005) (on file with the McGeorge Law Review) ("[T]he lag between the discovery of more effective forms
of treatment and their incorporation into routine patient care averages 17 years.").
8. See CAL. Bus. & PROF. CODE. § 2234.1(c) (amended by Chapter 304) (stating the legislative intent
behind section 2234.1).
9. See MERRIAM-WEBSTER DICTIONARY 754 (1997) (defining "tick" as "any of a large group of small
blood-sucking arachnids").
10. Raphael B. Stricker, Andrew Lautin & Joseph J Burrascano, Lyme Disease: Point/Counterpoint, 3
EXPERT REV. OF ANTI-INFECTIVE THERAPY 155 (2005).
11. Id.
12. Id. at 155-56.
13. Id. at 155.
14. Id.
15. See Gary P. Wormser et al., Practice Guidelines for the Treatment of Lyme Disease: Guidelines from
the Infectious Diseases Society of America, 31 CLINICAL INFECTIOUS DISEASES Si, Si-S14 (Supp. 2000)
(stating the guidelines for treating Lyme disease but not recognizing persistent Lyme disease as requiring more
than thirty days of antibiotic treatment).
16. Id.; Stricker et al., supra note 10, at 155.
17. Stricker et al., supra note 10, at 155.
18. See Raphael B. Stricker & Andrew Lautin, The Lyme Wars: Time to Listen, 12 EXPERT OPINION ON
INVESTIGATIONAL DRUGS 1609 (2003) (describing testimony made before members of Congress by one of the
nation's foremost experts on the treatment of Lyme disease, Dr. Joseph Burrascano of New York).
19. Stricker et. al., supra note 10, at 155.
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effective only if administered shortly after the tick bite occurs.20 This standard of
care causes a problem because many, if not the majority, of people infected are
not aware of the tick bite when it occurs and seek medical care only when
symptoms later emerge.2' When the disease is left untreated for weeks or months,
it can result in a persistent debilitating form of Lyme disease that requires
prolonged antibiotic treatment, lasting much longer than the thirty-day treatment
course recommended by the dominant view." In many cases, curing the disease
requires ten or more years of treatment. 2' The evidence-based guidelines
published by the International Lyme and Associated Diseases Society (ILADS)
recognize the emerging school of thought.24 However, the overwhelming majority
of physicians and the Medical Board of California do not embrace these
guidelines. 25 Dr. Herbert Dbrken, Legislation Advocate for the California Lyme
Disease Association (CLDA), describes the controversy: "Basically what we
have are 'Lyme Wars' between those biased to 30 days of short-term treatment
and those who on examination hold that longer-term care is essential. 26
The lack of recognition of persistent Lyme disease prior to the enactment of
Chapter 304 made the majority of physicians reluctant to diagnose it or
administer treatment to patients because of potential disciplinary action by the
Medical Board of California.27 The CLDA has stated that the lack of recognition
of persistent Lyme disease poses a serious problem for the effective treatment of
Lyme disease patients." Dr. Therese Yang's situation exemplified this problem.
She is a California physician who treats persistent Lyme disease; because she
recognized persistent Lyme disease and administered long-term antibiotic
treatment, Medical Board of California charged her with treating an infection that
does not exist.29 The disinclination of California physicians to diagnose and treat
20. See Stricker & Lautin, supra note 18, at 1610 (stating that the disease often goes undetected due to a
patient's failure to recognize that he or she has been bitten by a tick).
21. Id.
22. Stricker et. al., supra note 10, at 155.
23. See AMY TAN, OPPOSITE OF FATE 393 (2003) (describing author Amy Tan's experience with Lyme
disease).
24. INTERNATIONAL LYME AND ASSOCIATED DISEASES SOCIETY, EVIDENCE-BASED GUIDELINES FOR
THE MANAGEMENT OF LYME DISEASE 35 (Summer 2004).
25. Stricker Testimony, supra note 5.
26. See Letter from Herbert Dbrken, Legis. Advocate, Cal. Lyme Disease Ass'n, to the Assembly Bus.
and Prof. Comm., Cal. State Assembly (Mar. 12, 2005) (on file with the McGeorge Law Review) (arguing in
support of Assembly Bill 592).
27. See Letter from Lorraine Johnson, Executive Dir., Cal. Lyme Disease Ass'n, to Assembly Member
Leland Y. Yee, Cal. State Assembly (Mar. 29, 2005) (on file with the McGeorge Law Review) ("Fear of action
by the Medical Board [of California] has had a substantial chilling effect on the willingness of physicians within
the state to treat persistent Lyme disease").
28. Id.
29. See Anne Krueger, Santee's Dr. Yang: Saint or Sinner?, SAN DIEGO UNION TRIB., Apr. 2, 2005,
available at http://www.signonsandiego.com/uniontrib/20050402/news-lm2yang.htm (on file with the McGeorge
Law Review) (describing the predicament of Dr. Therese Yang in treating patients with persistent Lyme disease,
specifically Angel Vipond). Dr. Yang battles the Medical Board of California, which fails to recognize the
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Lyme disease commonly results in misdiagnosis or subjects patients to extreme
difficulty and expense in finding a physician who will treat persistent Lyme
disease; therefore, the actual sufferers are those California residents stricken with
persistent Lyme disease.30 The CLDA sponsored Chapter 304 as a preemptive
measure to protect physicians like Dr. Yang who administer treatment to patients
with persistent Lyme disease from action by the Medical Board of California.3'
Currently in California, it is estimated that fewer than forty physicians will
treat Lyme disease and fewer than ten physicians specialize in the treatment of
persistent Lyme disease." Of those ten specialized physicians, their waiting lists
consistently exceed five-hundred patients.33 Supporters of Chapter 304 hope it
will remove a major discouraging factor for physicians to treat Lyme disease,
3
1
will increase the number of physicians treating Lyme disease, and will increase
the likelihood that a Lyme disease patient will receive appropriate treatment. 35
III. LEGAL BACKGROUND
A. California's Medical Practices Act
California's Medical Practices Act ("Act"), originally enacted in 1876,
authorized the state to create policy and procedures pertaining to regulation and
of medicine. In 1937, the Act was codified in sectionslicensing for the practice e c  .3n13,te   ii  in
2000 through 2497 of the California Business and Professions Code.3 The Act
created the Medical Board of California, which protects the public by regulating
and licensing medical practices and creating disciplinary procedures for
violations of the Act.38
Moreover, the Act provides that the Medical Board of California may take
disciplinary action against a physician's license for engaging in unprofessional
existence of persistent Lyme disease. Instead, the Board diagnoses patients as "extremely troubled... with a severe
psychiatric illness." Id.
30. Statement to the Cal. Med. Bd., Div. of Med. Quality by Physicians Who Treat Persistent Lyme
disease (Feb. 17, 2005) (on file with McGeorge Law Review).
31. See Letter from Herbert Dorken to the Assembly Bus. and Prof. Comm, supra note 26 (pronouncing
the impetus behind the CLDA's sponsorship of Chapter 304).
32. Statement to the California Medical Board, supra note 30.
33. Id.; see also Letter from Therese H. Yang, to Assembly Member Leland Yee, Cal. State Assembly
(Apr. 3, 2005) (on file with McGeorge Law Review) (stating that Dr. Yang has treated over 600 patients with
Lyme disease, many of whom sought help from other doctors who denied the existence of Lyme disease in
California); see also Stricker Testimony, supra note 5 (testifying that he currently has over 600 Lyme disease
patients).
34. Statement to the California Medical Board, supra note 30.
35. Id.
36. See Ex parte Frazer, 54 Cal. 94, 95 (1880) (acknowledging the 1876 Act and discussing its initial
powers).
37. CAL. Bus. & PROF. CODE § 2000 (West 2003); see Sobey v. Molony, 40 Cal. App. 2d 381, 384, 104
P.2d 868, 870, (1940) (discussing the codification of the Medical Practices Act into the Business and
Professions Code).
38. CAL. BUS. & PROF. CODE § 2001.1.
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conduct.39 It defines unprofessional conduct to include gross negligence, repeated
negligent acts, and incompetence. 4°
Historically, the Act discouraged physicians and surgeons from treating
patients by means of non-conventional methods of medical care, even though
they had been determined safe and effective.4' Physicians feared that advising
patients on these methods would be considered a form of incompetence and
would subject the physician to disciplinary procedures by the Medical Board of
California likely resulting in loss of his or her medical license. 2
B. Business and Professions Code Sections 2500 and 250141
Business and Professions Code section 2500 acknowledges the interest of
physicians and patients in non-conventional methods of medical care" and requires
the Medical Board of California to establish policies and/or modify laws to "assure
California consumers the most advanced and innovative medical care."45 Section
2501 requires the Medical Board of California to set forth disciplinary policies and
procedures to reflect emerging and innovative medical practices for licensed
physicians.46
Due to the enactment of sections 2500 and 2501, the Medical Board of
California instituted a "Non-Conventional Medicine Committee" 7 for the purpose of
evaluating "alternative and complementary medicine" and its integration into the
common practice of medicine.4 ' After its creation, the Non-Conventional Medicine
Committee investigated the current need and usage of alternative and complementary
medicine and then developed the language for Business and Professions Code
section 2234.1, which Senate Bill 1691 enacted.49
39. Id. § 2234.
40. Id. § 2234(b)-(d).
41. ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 2100, at 3 (June 27, 2000).
42. Id.
43. CAL. Bus. & PROF. CODE §§ 2500-01 (as enacted by 2000 Cal. Stat. ch. 660).
44. Id. § 2500 (West 2003) (stating the interest and giving examples of non-conventional medical care as
"including, but not limited to, biopsychosocial techniques, nutrition, and the use of natural supplements to
enhance health and wellness").
45. Id.
46. Id. § 2501.
47. See Med. Bd. of Cal., Committees of the Medical Board of California, http://www.medbd.
ca.gov/Committees.htm (last visited June 23, 2005) (on file with the McGeorge Law Review) (listing the
members of the Non-Conventional Medicine Committee as Lorie G. Rice, M.P.H., Chair; William S. Breall,
M.D; Salma Haider; Ronald L. Morton, M.D.).
48. See ASSEMBLY FLOOR, FLOOR ANALYstS OF SB 1691, at 3 (Aug. 18, 2004) (stating that as a result of
the enactment of SB 2100, the Medical Board of California established the Non-Conventional Medicine
Committee and revised disciplinary policies and staff training).
49. See id. (describing the Non-Conventional Medicine Committee's involvement in the development of
SB 1691).
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C. Business and Professions Code Section 2234.150
Prior to its amendment by Chapter 304, Business and Professions Code
section 2234.1 created an exemption from discipline for physicians prescribing
"alternative or complementary medicine."5  There are four requirements to
qualify for the exception: 1) the physicians must acquire informed consent before
administering alternative or complementary medicine to the patient; 2 2) the
physicians must give the patient information regarding conventional treatments
and the physicians' pedigrees relating to their practice of alternative or
complementary medicine;53 3) the alternative or complementary medicine must
"not cause delay in, or discourage traditional diagnosis of, a condition of the
patient;" and 4) the alternative or complementary medicine must "not cause death
or serious bodily injury to the patient.
54
Section 2234.1 defines "alternative or complementary medicine" as "methods
of diagnosis, treatment, or healing that are not generally used but that provide a
reasonable potential for therapeutic gain in a patient's medical condition that is not
outweighed by the risk of the health care method. 55
Before Chapter 304, section 2234.1 provided that physicians who
administered alternative or complementary medical care would be protected from
discipline by the Medical Board of California. However, the alternative and
complementary exemption did not extend protection to physicians who
administered treatment of persistent Lyme disease.56
IV. CHAPTER 304
Chapter 304 amends Business and Professions Code section 2234. 17 and
furthers the goal of Business and Professions Code section 2500,58 which is to
assure California consumers that the quality of medicine in the state is the most
advanced and innovative it can be in terms of preserving health and providing
diagnosis and treatment of illness.59 Chapter 304 advances this goal by expanding
the scope of alternative and complementary medicine to include treatment of
50. Id. § 2234.1(as enacted by 2004 Cal. Stat. ch. 742).
51. Id. § 2234.1 (a) (West 2005).
52. Id. § 2234.1(a)(1).
53. Id. § 2234.1(a)(2).
54. Id. § 2234.1(a)(3)-(4).
55. Id. § 2234.1(b).
56. ASSEMBLY FLOOR, FLOOR ANALYSIS OF AB 592, at 3 (April 15, 2005).
57. Id.
58. See id. (stating the goals of California Business and Professions code section 2500 (enacted by SB
2100)); see also id. § 2500 (amended by Chapter 304) (acknowledging an interest by physicians and consumers
and requiring the boards-Medical Board of California and Osteopathic Medical Board of California-to
establish policies and/or modify law to assure California consumers the best possible medical care).
59. ASSEMBLY FLOOR, FLOOR ANALYSIS OF AB 592, at 3 (Apr. 15, 2005).
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persistent Lyme disease.60 Thus, a physician or surgeon will not be subject to
discipline for administering treatment of persistent Lyme disease so long as he or
she follows the appropriate procedures enumerated in section 2234.1.61
Finally, Chapter 304 states the legislative intent for section 2234.1 and the
reason for including persistent Lyme disease within the meaning of alternative
and complementary medicine.62 Chapter 304 also states:
Because the National Institute of Medicine has reported that it can take
up to 17 years for a new best practice to reach the average physician or
surgeon, attention must be given to new developments in general medical
care, as well as, the treatment of specific diseases, particularly those that




California follows the lead of the Rhode Island State legislature64 by enacting
Chapter 304 to protect physicians administering long term antibiotic treatment of
sease. 5 While the enactment of Chapter 304 will quellpersistent Lyme di  l65 cmeto e 4wl l
California physicians' apprehension about being disciplined by the Medical
Board of California for treating persistent Lyme disease, it is only one step
toward increasing treatment opportunities for those afflicted with this disease.
60. CAL. Bus. & PROF. CODE § 2234.1 (amended by Chapter 304).
61. See id. § 2234.1(a)(l)-(4) (West 2003). "A physician and surgeon shall not be subject to discipline
pursuant to subdivision (b), (c), or (d) of Section 2234 solely on the basis that the treatment or advice he or she
rendered to a patient is alternative or complementary medicine if that treatment or advice meets all of the
following requirements:
(1) It is provided after informed consent and a good-faith prior examination of the patient,
and medical indication exists for the treatment or advice, or it is provided for health or
well-being.
(2) It is provided after the physician and surgeon has given the patient information
concerning conventional treatment and describing the education, experience, and
credentials of the physician and surgeon related to the alternative or complementary
medicine he or she practices.
(3) It does not cause a delay in, or discourage traditional diagnosis of, a condition of the
patient.
(4) It does not cause death or serious bodily injury to the patient." Id.
62. ASSEMBLY FLOOR, FLOOR ANALYSIS OF AB 592, at 2 (Apr. 4, 2005).
63. CAL. Bus. & PROF. CODE § 2234.1(c); see ASSEMBLY FLOOR, ANALYSIS OF AB 592, at 3 (Apr. 4,
2005) (stating that the CLDA sponsors the bill because it seeks to protect physicians administering long-term
treatment of persistent Lyme disease).
64. See R.I. GEN. LAWS § 5-37.5-4 (2004) ("No physician is subject to disciplinary action by the board
solely for prescribing, administering or dispensing long-term antibiotic therapy for a therapeutic purpose for a
patient clinically diagnosed with Lyme disease .... ). The statute also lists the requirements the physician must
fulfill in order to receive the exemption from discipline. Id.
65. See ASSEMBLY FLOOR, FLOOR ANALYSIS OF AB 592, at 3 (Apr. 4, 2005) (stating that the sponsor of
the bill seeks to protect physicians administering long-term treatment of persistent Lyme disease).
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Still, there is a major hurdle to overcome before persistent Lyme disease
patients will have the availability of treatment that they require-insurance
coverage. Because insurance companies do not cover treatment of persistent
Lyme disease" and California does not have legislation in place requiring such
coverage (as Rhode Island and Connecticut do), 67 treatment of persistent Lyme
disease will be limited to patients with the financial means to support long term
antibiotic treatment.68
VI. CONCLUSION
The California Legislature has become aware of the Lyme disease epidemic
it is facing, and it has taken several strides forward to protect its citizens from
this disease. The first step came in 1999 when Senate Bill 1115 established the
Lyme disease Advisory Committee to provide educational materials and
information regarding Lyme disease in California.69 The next step came in April
of 2005 as the Legislature enacted Resolution Chapter 20 proclaiming May
fourth through May tenth as Lyme Disease Awareness week. 70 Now, Chapter 304
adds a level of protection to the physicians and surgeons of California who treat
Lyme disease and in turn those who suffer from it. Before Chapter 304,
66. See TAN, supra note 23 at 393 (describing author Amy Tan's experience with Lyme disease and the
fact that insurance companies, HMOs, and medical organizations do not recognize, nor cover long-term
treatment of persistent Lyme disease); see also Letter from Therese H. Yang to Assembly Member Leland Yee,
supra note 33 (stating that insurance companies disregard evidence based guidelines that recommend long-term
treatment of persistent Lyme disease, but recognize the evidence based guidelines that say such treatment is not
beneficial, and speculating that there is "an obvious conflict of interest").
67. See R.I. GEN. LAWS § 27-18-62 (2004) ("Every individual or group hospital or medical expense
insurance policy or individual or group hospital or medical services plan contract delivered, issued for delivery,
or renewed in this state on or after January 1, 2004 shall provide coverage for diagnostic testing and long-term
antibiotic treatment of chronic Lyme disease when determined to be medically necessary and ordered by a
physician acting in accordance with chapter 37.5 of title 5 entitled 'Lyme disease diagnosis and treatment' after
making a thorough evaluation of the patient's symptoms, diagnostic test results and response to treatment.
Treatment otherwise eligible for benefits pursuant to this section shall not be denied solely because such
treatment may be characterized as unproven, experimental, or investigational in nature. Provided, however, this
section shall not apply to insurance coverage providing benefits for: (1) Hospital confinement indemnity; (2)
Disability income; (3) Accident only; (4) Long-term care; (5) Medicare supplement; (6) Limited benefit health;
(7) Specified disease indemnity; (8) Sickness or bodily injury or death by accident or both; and (9) Other
limited benefit policies."); see also CONN. GEN. STAT. §§ 38a-492h (2004) ("Each individual health insurance
policy providing coverage of the type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-469
delivered, issued for delivery, renewed or continued in this state on or after January 1, 2000, shall provide
coverage for Lyme disease treatment including not less than thirty days of intravenous antibiotic therapy, sixty
days of oral antibiotic therapy, or both, and shall provide further treatment if recommended by a board certified
rheumatologist, infectious disease specialist or neurologist licensed in accordance with chapter 370 or who is
licensed in another state or jurisdiction whose requirements for practicing in such capacity are substantially
similar to or higher than those of this state.").
68. See Barbara L. Altwell, Mainstreaming Complementary and Alternative Medicine in the Face of
Uncertainty, 72 U.M.K.C. L. REV. 593, 594 (2004) (discussing the growing demand for alternative and
complementary medicine and the difficulty of receiving insurance coverage for non-conventional treatments).
69. CAL. HEALTH & SAFETY CODE §§ 104190-93 (West 2004).
70. RESOLUTION CHAPTER 20 (2005) (enacted by Senate Concurrent Resolution 23).
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physicians who treated persistent Lyme disease were subject to disciplinary
action by the Medical Board of California; after the enactment of Chapter 304
physicians no longer have to worry about such action.
While Chapter 304 accomplishes its purpose, to protect physicians who treat
persistent Lyme disease from disciplinary actions, the package will not be
complete until California enacts measures similar to Rhode Island and
Connecticut that will protect patients who seek treatment for persistent Lyme
disease from the exorbitant cost of long term antibiotics.
